GlassScriptPhysician profile
Timothy L Coleman
NPI 1730382128
$1,895.71
in general payments reported to CMS, 2019-2025
14 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $62.56 · 2021: $319 · 2022: $195 · 2023: $405 · 2024: $130 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $385.36 | 2025 | Uplizna |
| Medtronic, INC. | $332.31 | 2021-2024 | Linq II |
| Ucb, INC. | $215.23 | 2022-2025 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $208.75 | 2021-2023 | Ultomiris |
| Stryker Corporation | $139.17 | 2021-2024 | Trevo |
| Genentech USA, INC. | $137.05 | 2019 | |
| Janssen Biotech, INC. | $105.84 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $103.61 | 2019 | |
| Akcea Therapeutics, INC. | $62.56 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.00 | 2023 | Gammagard Liquid |
| Abbvie INC. | $48.88 | 2023-2025 | Botox |
| Boston Scientific Corporation | $46.72 | 2023-2024 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $30.69 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $19.54 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.